Guide for Authors

ONCOLOGY will not consider articles that are sponsored directly or indirectly by a commercial entity (eg, a pharmaceutical company or public relations firm). Financial Disclosure statements are published for all authors and reviewers.

Specifications
1. Manuscript should be no more than 10 to 12 typed pages (plus tables, references, and illustrations), printed on 8½ x 11-inch paper, double-spaced, with 1½-inch margins. Submit an electronic copy (including tables and art elements) via e-mail to cara.glynn@cmpmedica.com or by mail on a CD, DVD, or IBM PC-compatible disk, preferably as a Microsoft Word document.

2. All abbreviations should be explained at first mention. Use of abbreviations should be kept to a minimum.

3. Drugs-If a drug is not available generically and is marketed as no more than two trademarked or registered products, both generic and trade names should be given. The first time a drug is mentioned, the generic name should be followed by the trade name in parentheses. Thereafter, only the generic name should be used.

4. The title page should include the title of the article, all authors’ names, their academic and clinical appointments, and their primary affiliations, city and state, plus an address for future correspondence. The second page should contain an abstract of 200 words or less, summarizing the main points of the paper and the major conclusions.

5. Printouts of photos and slides should be labeled “top” and numbered to correlate with the figure legends included in the manuscript. Where appropriate on scans, include arrows pointing to the pathology as part of the graphic. Figures should be provided as electronic files in high-resolution JPG, PDF, TIF, EPS, or PPT format. Each table should appear on a separate sheet, numbered and titled. All tables and figures should be cited in text in numerical order, with associated references (from credit lines or listed studies) included at the point of table/figure callouts.

6. References should be limited to 40 and numbered consecutively as they appear in the text. The following modifications of Medline style should be used:

For Articles:
Keime-Guibert F, Chinot O, Taillandier L, et al: Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527-1535, 2007.

For Abstracts:
Hussein M, Berenson J, Niesvizky R, et al: Results of a phase I trial of SGN-40 (anti-huCD40 mAb) in patients with relapsed multiple myeloma (abstract 3576). Blood 108:1021a, 2006.

For Books:
Takimoto CH, Calvo E: Principles of oncologic pharmacotherapy, in Pazdur R, Coia LR, Hoskins WJ, et al (eds): Cancer Management: A Multidisciplinary Approach, 10th ed, pp 23-34. New York, CMPMedica, 2007.

For Web Citations:
National Cancer Institute: Melanoma risk assessment tool. Available at www.cancer.gov/melanomarisktool/. Accessed June 7, 2007.

Manuscripts and all accompanying material should be sent to:
Cara H. Glynn
Sr. Editorial Director, ONCOLOGY
CMPMedica, a division of UBM
600 Community Dr, 3^rd floor
Manhasset, NY 11030
Phone: (516) 734-2008

Fax: (516) 734-2018
e-mail: cara.glynn@cmpmedica.com